{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:52Z","timestamp":1792740772595,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006456","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,7,8]],"date-time":"2009-07-08T00:00:00Z","timestamp":1247011200000}}],"reference-count":116,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006456.pub2","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T11:05:03Z","timestamp":1246619103000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Therapeutic interventions for symptomatic treatment in Huntington's disease"],"prefix":"10.1002","author":[{"given":"Tiago","family":"Mestre","sequence":"first","affiliation":[{"name":"Institute of Molecular Medicine; Neurological Clinical Research Unit; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel M","family":"Coelho","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Rosa","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine; Neurological Clinical Research Unit; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0001|cit1","first-page":"397","article-title":"A controlled trial of fluoxetine in nondepressed patients with Huntington's disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov Disord 1997;12(3):397-401"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"10.1002\/14651858.CD006456.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"10","author":"Cubo","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.870100305","article-title":"L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia","volume":"5","author":"Goetz","year":"1990","journal-title":"Mov Disord"},{"issue":"2","key":"10.1002\/14651858.CD006456.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1212\/WNL.50.5.1366","article-title":"Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease.","volume":"50","author":"The Huntington Study Group","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.870110310","article-title":"A controlled trial of remacemide hydrochloride in Huntington's disease","volume":"11","author":"Kieburtz","year":"1996","journal-title":"Mov Disord"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0009|cit9","first-page":"16","article-title":"The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study","volume":"11","author":"Mateo","year":"1996","journal-title":"Neurologia"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","article-title":"Minocycline safety and tolerability in Huntington disease","volume":"63","author":"The Huntington study group","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0011|cit11","unstructured":"World Congress in Huntington\u00b4s disease 2007"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1212\/WNL.49.1.153","article-title":"Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease","volume":"49","author":"Murman","year":"1997","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006456.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A randomized trial of amantadine in Huntington disease","volume":"60","author":"O'Suilleabhain","year":"2003","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1002\/14651858.CD006456.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD006456.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","author":"The Huntington study group","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of Huntington's chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002826-198910000-00008","article-title":"Effects of terguride in patients with Huntington's disease","volume":"12","author":"Stocchi","year":"1989","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"The Huntington study group","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0019|cit19","unstructured":"The Huntington Study group TREND-HD - A Trial of Ethyl-EPA (Miraxion\u2122) in Treating Mild to Moderate Huntington's Disease World Congress in Huntington\u00b4s disease 2007"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00001756-200201210-00011","article-title":"A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids","volume":"13","author":"Vaddadi","year":"2002","journal-title":"Neuroreport"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study","volume":"63","author":"Vugt","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00002826-199510000-00005","article-title":"Acute challenge with apomorphine in Huntington's disease: a double-blind study","volume":"18","author":"Albanese","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archneur.1979.00500410100024","article-title":"Huntington's chorea and bromocriptine","volume":"36","author":"Albano","year":"1979","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0140-6736(74)92339-3","article-title":"Treatment of Huntington's chorea with lithium carbonate. A double-blind trial","volume":"1(7848)","author":"Aminoff","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31(8)","author":"Asher","year":"1981","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006456.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1212\/WNL.28.12.1280","article-title":"Long term treatment of Huntington disease with L-glutamate and pyridoxine","volume":"28","author":"Barr","year":"1978","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1212\/WNL.36.7.984","article-title":"Therapeutic experience with transdihydrolisuride in Huntington's disease","volume":"36(7)","author":"Bassi","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington's disease: an open label study","volume":"25(5)","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","article-title":"Clozapine in Huntington's chorea","volume":"44(5)","author":"Bonuccelli","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp.52.5.631","article-title":"Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders","volume":"52(5)","author":"Braun","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0033|cit33","first-page":"317","article-title":"The trial use of clozapine for abnormal involuntary movement disorders","volume":"136(3)","author":"Caine","year":"1979","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0035-3787(05)85174-4","article-title":"[Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia]","volume":"161(11)","author":"Caparros-Lefebvre","year":"2005","journal-title":"Rev Neurol (Paris)"},{"issue":"1-6","key":"10.1002\/14651858.CD006456.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000114879","article-title":"Pharmacology of Huntington\u00b4s disease. Personal experience","volume":"16","author":"Caraceni","year":"1977","journal-title":"Eur Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/jnnp.41.12.1114","article-title":"2-Dymethylaminoethanol (Deanol) in Huntington\u00b4s chorea","volume":"41","author":"Caraceni","year":"1978","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0037|cit37","first-page":"155","article-title":"Effects of DA agonist in Huntington disease hyperkinesia","volume":"1","author":"Caraceni","year":"1980","journal-title":"Ital J Neurol Sci"},{"issue":"7861","key":"10.1002\/14651858.CD006456.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(74)92881-5","article-title":"Huntington\u00b4s chorea treated with lithium carbonate","volume":"1","author":"Carman","year":"1974","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1978.00500250031006","article-title":"Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor","volume":"35(1)","author":"Corsini","year":"1978","journal-title":"Arch Neurol"},{"issue":"5654","key":"10.1002\/14651858.CD006456.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","article-title":"Effect of tetrabenazine on extrapyramidal movement disorders","volume":"2","author":"Dalby","year":"1969","journal-title":"Br Med J"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","article-title":"Effectiveness of risperidone in Huntington chorea patients","volume":"19(1)","author":"Dallocchio","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"10.1002\/14651858.CD006456.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington's disease","volume":"19","author":"Tommaso","year":"2004","journal-title":"Mov Disord"},{"issue":"6","key":"10.1002\/14651858.CD006456.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","article-title":"Efficacy of levetiracetam in Huntington disease","volume":"28","author":"Tommaso","year":"2005","journal-title":"Clin. Neuropharmacol"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","article-title":"Two years\u2019 follow-up of rivastigmine treatment in Huntington Disease","volume":"30","author":"Tommaso","year":"2007","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000115683","article-title":"Effect of piracetam in Huntington's chorea","volume":"23(2)","author":"Dest\u00e9e","year":"1984","journal-title":"Eur Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0046|cit46","first-page":"488","article-title":"Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities","volume":"57(6)","author":"Dupont","year":"1978","journal-title":"Acta Neurol Scand"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington's disease","volume":"15(1)","author":"Fernandez","year":"2000","journal-title":"Mov Disord"},{"issue":"7856","key":"10.1002\/14651858.CD006456.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(74)92809-8","article-title":"Letter: G.A.B.A. in Huntington\u00b4s chorea","volume":"1","author":"Fisher","year":"1974","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006456.pub2-BIB0049|cit49","first-page":"605","article-title":"Huntington\u00b4s chorea","volume":"126","author":"Fisher","year":"1982","journal-title":"Can Med Assoc J"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0404.1970.tb05621.x","article-title":"Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes","volume":"46(2)","author":"Fog","year":"1970","journal-title":"Acta Neurol Scand."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.33.5.637","article-title":"THIP treatment of Huntington's disease","volume":"33(5)","author":"Foster","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(83)90042-4","article-title":"Acute treatment of Huntington's chorea with lisuride","volume":"59(2)","author":"Frattola","year":"1983","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1002\/14651858.CD006456.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(83)90042-4","article-title":"Acute treatment of Huntington's chorea with lisuride","volume":"59","author":"Frattola","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0054|cit54","first-page":"282","article-title":"[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]","volume":"4(8)","author":"Gim\u00e9nez-Rold\u00e1n","year":"1989","journal-title":"Neurologia"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-0028-1094549","article-title":"[Influence of the Benzodiazepine-derivative Ro 06-9098\/000 on choreo-athetotic syndromes (author's transl)]","volume":"10(5)","author":"Girke","year":"1977","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"issue":"8","key":"10.1002\/14651858.CD006456.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","article-title":"Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease","volume":"47","author":"Girotti","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006456.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002826-199204000-00009","article-title":"Glutamatergic therapy of Huntington's chorea","volume":"15","author":"Giuffra","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"7925","key":"10.1002\/14651858.CD006456.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(75)90043-4","article-title":"Letter: Amantadine in chorea","volume":"2","author":"Gray","year":"1975","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jnnp.30.2.185","article-title":"Cellular magnesium levels and the use of penicillamine in the treatment of Huntington's chorea","volume":"30(2)","author":"Haslam","year":"1967","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.63.3.597","article-title":"IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study","volume":"63(3)","author":"Heckmann","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11(1)","author":"Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archneur.1976.00500070059012","article-title":"Bromocriptine in Huntington chorea","volume":"33(7)","author":"Kartzinel","year":"1976","journal-title":"Arch Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1191\/0269215503cr582oa","article-title":"Effects of multisensory stimulation in people with Huntington's disease: a randomized controlled pilot study.","volume":"17(1)","author":"Leng","year":"2003","journal-title":"Clin Rehabil"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A double blind trial of lithium carbonate and haloperidol in Huntington's chorea","volume":"9(2)","author":"Leonard","year":"1975","journal-title":"Aust N Z J Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006456.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s100720200081","article-title":"Amantadine in Huntington's disease: open-label video-blinded study","volume":"23","author":"Lucetti","year":"2002","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1002\/14651858.CD006456.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","article-title":"IV amantadine improves chorea in Huntington's disease: an acute randomized controlled study","volume":"60","author":"Lucetti","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.410100107","article-title":"Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease","volume":"10(1)","author":"Manyam","year":"1981","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1002\/14651858.CD006456.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(74)90183-4","article-title":"Letter: Buronil in Huntington's chorea","volume":"30","author":"Mattsson","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(74)92338-1","article-title":"A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea","volume":"1(7848)","author":"McLellan","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.28.10.1061","article-title":"Treatment of Huntington disease with a cholinergic agonist","volume":"28(10)","author":"Nutt","year":"1978","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006456.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/archneur.1978.00500360034006","article-title":"Effect of an opiate antagonist on movement disorders","volume":"35","author":"Nutt","year":"1978","journal-title":"Arch Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington's disease-associated chorea","volume":"25(6)","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0404.1968.tb05581.x","article-title":"The effect of tetrabenazine in some hyperkinetic syndromes","volume":"44","author":"Pakkenberg","year":"1968","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1002\/14651858.CD006456.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington's disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1002\/14651858.CD006456.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archneur.1977.00500170062012","article-title":"Valproate sodium in Huntington chorea","volume":"34","author":"Pearce","year":"1977","journal-title":"Arch Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/WNL.32.4.354","article-title":"A double-blind clinical trial of isoniazid in Huntington disease","volume":"32(4)","author":"Perry","year":"1982","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1212\/WNL.30.7.772","article-title":"Failure of aminooxyacetic acid therapy in Huntington disease","volume":"30(7 Pt 1)","author":"Perry","year":"1980","journal-title":"Neurology."},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1212\/WNL.29.3.370","article-title":"Isoniazid therapy in Huntington disease","volume":"29","author":"Perry","year":"1979","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0079|cit79","first-page":"107","article-title":"[Treatment of choreic syndromes with sodium dipropylacetate]","volume":"47(2)","author":"Piccinin","year":"1977","journal-title":"Riv Neurol"},{"issue":"7","key":"10.1002\/14651858.CD006456.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-2003-815024","article-title":"Amisulpride in Huntington's disease","volume":"32","author":"Saft","year":"2005","journal-title":"Psychiatr Prax"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-6-11","article-title":"Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series","volume":"28;6","author":"Saft","year":"2006","journal-title":"BMC Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.34.1.94","article-title":"Gamma-vinyl GABA treatment of Huntington's disease","volume":"34(1)","author":"Scigliano","year":"1984","journal-title":"Neurology."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0083|cit83","first-page":"1325","article-title":"Amantadine and Huntington's chorea","volume":"285(23)","author":"Scotti","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0084|cit84","first-page":"866","article-title":"Riluzole in Huntington's disease (HD): an open label study with one year follow-up","volume":"248(10)","author":"Seppi","journal-title":"J Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0085|cit85","first-page":"504","article-title":"Letter: Huntington's disease: treatment with imidazole-4-acetic acid","volume":"293(10)","author":"Shoulson","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ana.410040316","article-title":"Huntington's disease: treatment with muscimol, a GABA-mimetic drug","volume":"4(3)","author":"Shoulson","year":"1978","journal-title":"Ann Neurol."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.36.8.1099","article-title":"Huntington's disease: effect of cysteamine, a somatostatin-depleting agent","volume":"36(8)","author":"Shults","year":"1986","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0088|cit88","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.35.2.186","article-title":"Treatment of involuntary movement disorders with tetrabenazine","volume":"35(2)","author":"Swash","year":"1972","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006456.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/ajp.135.3.352","article-title":"Sodium valproate in Huntington's disease","volume":"135","author":"Symington","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archneur.1977.00500240044007","article-title":"Deanol acetamidobenzoate treatment in choreiform movement disorders","volume":"34(12)","author":"Tarsy","year":"1977","journal-title":"Arch Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1212\/WNL.31.2.207","article-title":"Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration","volume":"31(2)","author":"Tell","year":"1981","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0093|cit93","first-page":"177","article-title":"Fluphenazine decanoate in the treatment of chorea: a double-blind study.Curr Ther Res Clin Exp. 1976 Aug;20(2):177-83.","volume":"20(2)","author":"Terrence","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0094|cit94","first-page":"223","article-title":"Studies on the anti-dyskinesia effect of apomorphine in man","volume":"17(4)","author":"Tolosa","year":"1976","journal-title":"Neurol Neurocir Psiquiatr"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.22.11.1201","article-title":"Administration of 5-hydroxy-L-tryptophan to individuals with Huntington's chorea","volume":"22(11)","author":"Tourian","year":"1972","journal-title":"Neurology"},{"issue":"39","key":"10.1002\/14651858.CD006456.pub2-BIB0096|cit96","first-page":"2141","article-title":"Electroconvulsive therapy in patients with Huntington's disease and depression","volume":"149","author":"Duijn","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-0447.1977.tb03561.x","article-title":"Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial","volume":"56(3)","author":"Vestergaard","year":"1977","journal-title":"Acta Psychiatr Scand"},{"issue":"16","key":"10.1002\/14651858.CD006456.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/mds.21718","article-title":"Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial","volume":"22","author":"Vitale","year":"2007","journal-title":"Mov. Disord"},{"issue":"4","key":"10.1002\/14651858.CD006456.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00002826-198908000-00010","article-title":"An open label trial of dextromethorphan in Huntington's disease","volume":"12","author":"Walker","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(74)90184-6","article-title":"Letter: Lithium in Huntington's chorea","volume":"2(7892)","author":"Worrall","year":"1974","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006456.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/mds.21061","article-title":"Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease","volume":"21","author":"Zesiewicz","year":"2006","journal-title":"Mov Disord"},{"issue":"7","key":"10.1002\/14651858.CD006456.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269215507075495","article-title":"Effects of an intensive rehabilitation programme on patients with Huntington's disease: A pilot study","volume":"21","author":"Zinzi","year":"2007","journal-title":"Clin. Rehabil"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0103|cit103","unstructured":"Curtis A World Congress of Huntington\u00b4s disease"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0104|cit104","unstructured":"Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomised, Placebo-Controlled Crossover Study Ongoing study November 2005."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0105|cit105","unstructured":"A randomised, placebo-controlled pilot study in Huntington's Disease (CIT-HD). Ongoing study November 2005."},{"key":"10.1002\/14651858.CD006456.pub2-BIB0106|cit106","unstructured":"A pilot study of Memantine for cognitive and behavioral dysfunction in Huntington's disease. Ongoing study"},{"issue":"21","key":"10.1002\/14651858.CD006456.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u00b4s disease: an evidence-based review","volume":"12","author":"Bonneli","year":"2005","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0108|cit108","unstructured":"www.cochrane.org\/resources\/handbook\/"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0109|cit109","first-page":"262","article-title":"Riluzole in Huntington\u00b4s disease: a 3 year, randomised controlled study","volume":"62(3)","author":"European Huntington Disease Initiative Study Group","year":"2007","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006456.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: Reliability and consistency","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD006456.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jmg.31.11.872","article-title":"Trinucleotide repeat length and progression of illness in Huntington's disease","volume":"31(11)","author":"Kieburtz","year":"1994","journal-title":"J Med Genet"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/088307389501000112","article-title":"George Huntington and hereditary chorea","volume":"10(1)","author":"Lanska","year":"1995","journal-title":"J Child Neurol"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0114|cit114","unstructured":"Review Manager (RevMan) [MacOSX]. Version 5.0. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration 2008"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0115|cit115","volume-title":"Principles of Neurology","author":"Ropper","year":"2005"},{"key":"10.1002\/14651858.CD006456.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome","volume":"72","author":"THsDCR","year":"1993","journal-title":"Cell"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006456.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:59:42Z","timestamp":1628546382000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006456.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":116,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006456.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}